STAMP: Surgically Treated Adjuvant Merkel cell Carcinoma with Pembrolizumab a Phase III Trial (ECOG EA6174) | NYU Langone Health

Go Back to All Clinical Trials

STAMP: Surgically Treated Adjuvant Merkel cell Carcinoma with Pembrolizumab a Phase III Trial (ECOG EA6174)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Merkel Cell Cancer
Age: Between 18 years - 100 years
Gender: Male or Female

Other Inclusion Criteria:

Patient must have a histological confirmation of diagnosis of Merkel cell carcinoma (MCC), pathologic stages (American Joint Committee on Cancer [AJCC] version 8) I-IIIb. Stage I patients with negative sentinel lymph node biopsy are ineligible. Patients who have a positive biopsy or for whom no biopsy was done are eligible.

You may not be eligible for this study if the following are true:

1. Patients with distant metastatic disease (stage IV). 2. Patients with a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis. 3. Patient with a history of distant metastatic disease.